These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 9377614)
1. Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Medansky RS; Cuffie CA; Tanner DJ Clin Ther; 1997; 19(4):701-9. PubMed ID: 9377614 [TBL] [Abstract][Full Text] [Related]
2. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819 [TBL] [Abstract][Full Text] [Related]
3. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Guenther LC; Poulin YP; Pariser DM Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233 [TBL] [Abstract][Full Text] [Related]
4. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. Tiplica GS; Salavastru CM J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):905-12. PubMed ID: 19470062 [TBL] [Abstract][Full Text] [Related]
5. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Medansky RS; Bressinck R; Cole GW; Deeken JH; Ellis CN; Guin JD; Herndon JH; Lasser AE; Leibsohn E; Menter MA Cutis; 1988 Nov; 42(5):480-5. PubMed ID: 3058398 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921 [TBL] [Abstract][Full Text] [Related]
7. A novel formulation of mometasone furoate in psoriasis patients: a multicenter, randomized, double-blind clinical study. Berg M; Svensson A; Faergemann J Adv Ther; 2013 May; 30(5):503-16. PubMed ID: 23709257 [TBL] [Abstract][Full Text] [Related]
8. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815 [TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Stjärne P; Mösges R; Jorissen M; Passàli D; Bellussi L; Staudinger H; Danzig M Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):179-85. PubMed ID: 16490876 [TBL] [Abstract][Full Text] [Related]
10. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. Green L; Sadoff W J Cutan Med Surg; 2002; 6(2):95-102. PubMed ID: 11992180 [TBL] [Abstract][Full Text] [Related]
12. Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential. Katz HI; Prawer SE; Watson MJ; Scull TA; Peets EA Int J Dermatol; 1989 Jun; 28(5):342-4. PubMed ID: 2753592 [No Abstract] [Full Text] [Related]
13. Comparison of amcinonide ointment 0.1 percent twice daily and fluocinonide ointment 0.05 percent three times daily in the treatment of psoriasis. Cornell RC Cutis; 1983 May; 31(5):566-9. PubMed ID: 6851655 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity. Kecskés A; Heger-Mahn D; Kuhlmann RK; Lange L J Am Acad Dermatol; 1993 Oct; 29(4):576-80. PubMed ID: 8408793 [TBL] [Abstract][Full Text] [Related]
15. Comparison of 0.25% desoxymethasone ointment with 0.05% fluocinonide ointment in psoriasis. Kuokkanen K Curr Med Res Opin; 1976-1977; 4(10):703-5. PubMed ID: 800971 [TBL] [Abstract][Full Text] [Related]
16. A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. Dutz JP; Lui H Int J Dermatol; 1998 Jan; 37(1):51-3. PubMed ID: 9522242 [TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with amcinonide 0.1 percent and fluocinonide 0.05 percent ointments. A comparative double-blind study. Engel MF Cutis; 1982 Jun; 29(6):646-50. PubMed ID: 7049592 [TBL] [Abstract][Full Text] [Related]
18. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. Meltzer EO; Jalowayski AA; Orgel HA; Harris AG J Allergy Clin Immunol; 1998 Jul; 102(1):39-49. PubMed ID: 9679846 [TBL] [Abstract][Full Text] [Related]
19. Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment. Nissen JB; Avrach WW; Hansen ES; Stengaard-Pedersen K; Kragballe K Dermatology; 1999; 198(1):11-7. PubMed ID: 10026395 [TBL] [Abstract][Full Text] [Related]
20. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Sharpe M; Jarvis B Drugs; 2001; 61(9):1325-50. PubMed ID: 11511026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]